Waf1/Cip1/CDKN1A p21 Antibody (AC8.3): sc-53393

p21 Waf1/Cip1 Antibody (AC8.3) is a mouse monoclonal IgG1 antibody raised against p21 Waf1/Cip1 in human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and immunohistochemistry. p21 Waf1/Cip1 plays a pivotal role in cell cycle regulation by serving as a potent inhibitor of cyclin-dependent kinases (Cdks), which drive the progression of the cell cycle through sequential activation. By tightly binding Cdks, p21 Waf1/Cip1 prevents the phosphorylation of key substrates, such as retinoblastoma protein (Rb), a critical step for advancing the cell cycle from the G1 phase to the S phase where DNA replication occurs. This arrest allows the cell to repair damage or resolve external stress signals, maintaining genomic stability. In addition to its p53-dependent induction in response to DNA damage, p21 Waf1/Cip1 also integrates signals from other pathways, allowing cells to exit the cycle temporarily (quiescence) or permanently (senescence). This capacity to coordinate these decisions underscores p21 Waf1/Cip1′s central role in preventing aberrant cell proliferation, which is a hallmark of cancer. The balance p21 Waf1/Cip1 maintains between cell cycle progression and arrest demonstrates its importance in cellular homeostasis, tumor suppression, and therapeutic research. Anti-p21 Waf1/Cip1 antibody (AC8.3) is an indispensable tool for probing the complexities of cell cycle regulation and p53-mediated tumor suppression.

The preferred Waf1/Cip1/CDKN1A p21 antibody is Waf1/Cip1/CDKN1A p21 Antibody (F-5): sc-6246.